CA
NZ
UK
AU
IND
US
Harrow, Inc. (NASDAQ: HROW) announced a second-quarter revenue of $70.7 million, up 60% sequentially but reporting an EPS of $-0.34, below the consensus estimate of $-0.18. This performance highlights ongoing challenges, as shares have dropped 18.5% year-to-date, indicating investor caution despite significant revenue growth.
Mesa Laboratories Inc (NASDAQ: MLAB) announced a notable increase in operating income, rising 129% to $7.03 million for the first fiscal quarter ending June 30, 2026. This result significantly outperformed analyst expectations, which forecastedEarnings Per Share(EPS) of only $0.03, as the company instead reported …
Nkarta, Inc. (NASDAQ: NKTX) reported a second-quarter net loss of $40.4 million, translating to an earnings per share (EPS) of $-0.54, which fell short of the $-0.38 consensus estimate. The miss comes as Nkarta, involved in developing engineered NK cell therapies for autoimmune diseases, …
Nu Skin Enterprises (NYSE: NUS) reported a Q2 loss of $5.14 per share, but its adjustedEarnings Per Shareof $0.20 indicated some resilience compared to the prior-year loss of $0.43 per share.
The substantial revenue contributing to this performance was $386 million, reflecting a 9% year-over-year increase that underscores the company’s strategic initiatives. Dr. Aric Coffman, CEO, noted that the results highlight the progress made in operational efficiencies, indicating a stable path forward for profitability and …
Annexon, Inc. (NASDAQ: ANNX) has appointed Mark S. Blumenkranz, M.D. To its board of directors, effective August 10, 2026. ThisLeadershipchange follows Muneer Satter's resignation, who has served on the board for over 11 years. The addition of Dr. Blumenkranz, a seasoned ophthalmology expert, underscores …
Bionano Genomics, Inc. reported a total revenue of $8.2 million for Q2 2026, representing a substantial 21% increase from the same quarter in 2025. This figure exceeds a consensus estimate of $-0.70 in earnings per share, with the actual EPS reported at $-0.64. The …
Ceribell, Inc. (NASDAQ: CBLL) achieved total revenue of $28.1 million for the quarter ended June 30, 2026, marking a substantial 33% increase from $21.2 million in Q2 2025. This growth comes against the backdrop of a consensus EPS estimate of $-0.48, as the company's …
DiaMedica Therapeutics (NASDAQ: DMAC) reported earnings per share of $-0.19 for the quarter ended June 30, 2026, edging the consensus forecast of $-0.20. The company also disclosed a cash balance of $43.5 million, a figure that supports a projected runway through 2027.
Enanta Pharmaceuticals (NASDAQ: ENTA) reported revenue of $14.4 million for the fiscal third quarter ended June 30, 2026, falling short of the $18.3 million from the same quarter last year. The net loss widened to $19.5 million, or $0.67 per share, compared to a …
Please wait processing your request...